Table 1.
Characteristics of patients included in study.
| Characteristic | Statistics |
|---|---|
| N | 3,164 |
| Age at PD-(L)1 Initiation | |
| Mean (SD) | 67.7 (10.6) |
| Median (Q1, Q3) | 69.0 (61.0, 75.0) |
| Age categories at PD-(L)1 Initiation | |
| < 49 | 142 (4.5%) |
| 50–64 | 1063 (33.6%) |
| 65–74 | 1063 (33.6%) |
| >/=75 | 896 (28.3%) |
| Age at Diagnosis | |
| Mean (SD) | 66.8 (10.6) |
| Median (Q1, Q3) | 68.0 (60.0, 74.0) |
| Gender | |
| Male | 1763 (55.7%) |
| Female | 1401 (44.3%) |
| Census Region | |
| Midwest | 980 (31.1%) |
| Northeast | 519 (16.5%) |
| South | 1362 (43.2%) |
| West | 303 (9.6%) |
| Race | |
| White | 2117 (66.9%) |
| Black | 357 (11.3%) |
| Hispanic | 163 (5.2%) |
| Asian | 61 (1.9%) |
| Unknown | 466 (14.7%) |
| PD-(L)1 therapy type | |
| Nivolumab | 2145 (67.8%) |
| Pembrolizumab | 905 (28.6%) |
| Atezolizumab | 114 (3.6%) |
| Days from diagnosis to first immunotherapy | |
| Mean (SD) | 366.1(401.6) |
| Median (Q1,Q3) | 236.0 (95.5, 472.5) |
| Time on Treatment | |
| Mean (SD) | 160.58 (160.12) |
| Median (Q1, Q3) | 112 (49, 215) |
| Line number of first immunotherapy | |
| First | 1047 (33.1%) |
| Second | 1623 (51.3%) |
| Third | 404 (12.8%) |
| Fourth or higher | 90 (2.8%) |